Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a drug calm severe eczema itch when the rash is mild? a new study investigates

NCT ID NCT06192563

Recruiting now Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study looks at teenagers aged 12 to 17 who have severe atopic dermatitis (eczema) with intense itching but only a mild to moderate rash. They are being treated with dupilumab (Dupixent), a standard medication. The goal is to see how well dupilumab controls itching, improves sleep and quality of life, and affects eczema in sensitive areas like the face, hands, and genitals. Researchers will follow participants for 52 weeks to track these outcomes in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dupilumab (Dupixent)
What this could lead to
If successful, this could show that dupilumab helps teens with severe itching even when their eczema rash is not widespread, improving sleep, daily life, and sensitive skin areas.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It is also limited to a specific group of teens in Italy, so findings may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS DERMATITIS ATOPIC

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Investigational Site Number: 001

    RECRUITING

    Milan, 20122, Italy

  • Investigational Site Number: 002

    RECRUITING

    Bologna, 40138, Italy

  • Investigational Site Number: 004

    RECRUITING

    Florence, 50139, Italy

  • Investigational Site Number: 005

    RECRUITING

    Roma, 00133, Italy

  • Investigational Site Number: 006

    RECRUITING

    Brescia, 25123, Italy

  • Investigational Site Number: 009

    RECRUITING

    Roma, 00168, Italy

  • Investigational Site Number: 010

    RECRUITING

    Naples, 80131, Italy

  • Investigational Site Number: 011

    RECRUITING

    Naples, 80138, Italy

  • Investigational Site Number: 014

    RECRUITING

    Verona, 37134, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.